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This Month in the Journal
This month in the Journal, Wang et al. describe how
mouse-human comparative genetics can be used to iden-
tify human genes associated with a complex trait, spe-
cifically atherosclerosis. There are at least 27 unique hu-
man QTLs for atherosclerosis, but few genes have been
reliably associated with this trait. However, about half
of the QTLs found in mouse models of atherosclerosis
have concordant human QTLs. Wang et al. explain how
this overlap can be used to identify the causative genes
within these QTLs and the types of mouse crosses that
will facilitate gene identification. In fact, the authors
have successfully used the general approach they de-
scribe to identify the TNFSF4 gene as being associated
with the risk of heart attack and coronary artery disease
in humans.
Mutations in SLC19A3 Cause BBGD, by Zeng et al.
(p. 16)
In this issue of the Journal, two articles report trans-
porter defects that are associated with neurological phe-
notypes. The first, by Zeng et al., is an investigation of
biotin-responsive basal ganglia disease (BBGD). This dis-
order first appears in children as a subacute encepha-
lopathy, with confusion and vomiting. It progresses to
acute encephalopathy, with speech difficulties, inability
to swallow, seizures, and partial or complete paralysis.
These symptoms can be completely reversed if treatment
with high doses of biotin is started at an early stage;
without continuous treatment, there is progressive en-
cephalopathy and, ultimately, death. The dramatic im-
provements with treatment placed biotin metabolism as
a key player in this disorder. Unfortunately, no defects
in the enzymes that require biotin were found. Linkage
analysis placed the critical region on chromosome 2, and
Zeng et al. focused on SLC19A3 as a candidate gene
because it belongs to a family of transporter proteins.
They found mutations in SLC19A3 in all four families
they examined. Because BBGD is so effectively treated
with biotin, the authors speculate that SLC19A3 encodes
a biotin transporter, a hypothesis supported by the recent
finding that people with induced biotin deficiency have
reductions in SLC19A3 mRNA levels in their blood.
Curiously, the presentation of BBGD seems to have neu-
rological specificity. Affected individuals do not have evi-
dence of a generalized biotin deficiency; therefore, the
biotin insufficiency appears to be limited to the brain.
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Allan-Herndon-Dudley Syndrome, by Schwartz et al.
(p. 41)
The second article that reports a transporter defect is by
Schwartz et al., who found a transporter defect in Allan-
Herndon-Dudley syndrome. This is a severe form of X-
linked mental retardation that is associated with hypo-
tonia, delayed motor development, and muscle hypo-
plasia. Linkage studies had placed the candidate gene in
the region of Xq13–Xq21. Schwartz et al. realized that
MCT8 was a good candidate gene in this region because
mutations in this gene have recently been reported in
males with mental retardation, hypotonia, and thyroid
abnormalities. Schwartz et al. studied six kindreds and
found that some of the affected individuals did, in fact,
have thyroid abnormalities, and all of them had muta-
tions in MCT8. This gene encodes the monocarboxylate
transporter 8, which has recently been shown to be a
thyroid-hormone transporter. The association with thy-
roid abnormalities could help to prioritize individuals
with X-linked mental retardation for MCT8 mutation
screening. As with the SLC19A3 mutations above, there
is specificity for the presentation of the transporter de-
fect, because individuals with MCT8 mutations don’t
show the effects of a general thyroid disturbance. Dumi-
trescu et al. (74:168–175) speculated that the severe neu-
rological phenotype coupled with mild evidence of a thy-
roid disturbance in people with MCT8 mutations could
suggest a brain-specific function for MCT8 beyond its
action as a hormone transporter.
Segmental Duplication Array CGH, by Sharp et al. (p.
78)
Segmental duplications have been associated with sev-
eral recurrent genomic disorders and are thought to be
prone to instability. With recent reports that there is
normal copy-number variation in the human genome, it
seemed likely that segmental duplications might also me-
diate the generation of some of this variation. To test
this hypothesis, Sharp et al. developed a microarray of
BACs containing regions of segmental duplication and
analyzed the DNA of 47 individuals from different popu-
lations to assess normal copy-number polymorphism
(CNP) in these genetic regions. This approach was cer-
tainly successful in identifying CNPs; 119 regions of
CNP were found, 73 of them novel. Compared with
control BACs, CNPs were enriched in regions that were
flanked by or contained segmental duplications, sup-
porting the theory that these duplications mediate the
generation of normal genetic variation. Not only did
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these duplications seem to generate CNPs, but they were
also often variant in copy number themselves. Sharp et
al. have created a Web-based database that includes their
results and that they hope will serve as a resource for
facilitating further studies of structural polymorphisms.
AR Is the Major Determinant of AGA, by Hillmer et
al. (p. 140)
Hillmer et al. report that a major determinant of male-
pattern baldness (androgenetic alopecia) is the androgen
receptor (AR) gene. In a sample of families with at least
two affected brothers, they found linkage to the X chro-
mosome in a region containing AR. This finding led the
authors to do an association study of markers in the area,
and they report a 1-Mb region that is strongly associated
with baldness in both a case-control and a family-based
association analysis. The only known gene within this
region is AR, and a GGN repeat is the only specific
feature in this gene that shows a strong association with
baldness. Previously, it was shown that there is allele-
specific variation in protein and activity levels for the
GGN repeat, so this association may have functional
significance. Alternatively, the GGN repeat could instead
be in linkage disequilibrium with the actual but as-yet-
undetected causal variation. Although it appears to con-
tribute significantly to male-pattern baldness, AR is ob-
viously not the whole story behind this phenotype, be-
cause its location on the X chromosome cannot explain
the fact that many sons resemble their fathers in terms
of baldness.
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